Market Place
Sourcing Support
Teva`s Austedo Shows Real-World Benefits In Tardive Dyskinesia
07 Nov 2025 //
GLOBENEWSWIRE
Teva Reports 11th Consecutive Quarter Of Growth
06 Nov 2025 //
INDPHARMAPOST
Teva`s Innovative Portfolio Drives Quarter of Growth in Q3 2025
05 Nov 2025 //
GLOBENEWSWIRE
Enforcement Report - Week of November 5, 2025
05 Nov 2025 //
FDA
Teva CEO Touts `Defining Strength` Of Innovative Drugs
05 Nov 2025 //
FIERCE PHARMA
Teva Drafts Terrell Davis For Tardive Dyskinesia Awareness Drive
05 Nov 2025 //
FIERCE PHARMA
Teva To Present at UBS & Jefferies Healthcare Conferences
31 Oct 2025 //
GLOBENEWSWIRE
Teva Settles Asthma Inhaler Antitrust Lawsuit For $35M
27 Oct 2025 //
REUTERS
Teva’s Generics Dalbavancin Hydrochloride Receives Approval in US
23 Oct 2025 //
FDA
Teva, Prestige Bio Sign Deal For Tuznue® Commercialization
20 Oct 2025 //
GLOBENEWSWIRE
FDA Approves UZEDY® For Bipolar I Disorder In Adults
10 Oct 2025 //
GLOBENEWSWIRE
FDA Approves Another Generic Version of Abortion Pill
03 Oct 2025 //
REUTERS
Teva Releases Q3 2025 Aide Memoire
25 Sep 2025 //
GLOBENEWSWIRE
Teva To Discuss Q3 2025 Financial Results In Conference Call
25 Sep 2025 //
GLOBENEWSWIRE
Teva And Medincell`s Risperidone Lai Receives Health Canada
23 Sep 2025 //
PHARMAWEB
Bausch, Teva Accused of Delaying Generic Xifaxan
23 Sep 2025 //
REUTERS
Teva Reveals Promising SOLARIS Results for Olanzapine LAI
23 Sep 2025 //
INDPHARMAPOST
Medincell, Teva to Host Investor Call on Phase 3 Olanzapine LAI
17 Sep 2025 //
PHARMAWEB
Teva to Release Ph 3 SOLARIS Olanzapine LAI Data Sep 22, 2025
16 Sep 2025 //
GLOBENEWSWIRE
Teva`s Generics Macitentan Receives Tentative Approval in US
15 Sep 2025 //
FDA
Corcept Faces Teva Lawsuit Over Mifepristone `Monopoly`
15 Sep 2025 //
REUTERS
FDA Fast Tracks Teva`s Emrusolmin
09 Sep 2025 //
GLOBENEWSWIRE
Colorado to Face Teva`s Lawsuit Over Allergy Pen Law
05 Sep 2025 //
REUTERS
Teva to Present at September Healthcare Conferences
02 Sep 2025 //
GLOBENEWSWIRE
Teva Brings 1st GLP-1 Generic for Obesity, Targets Novo’s Saxenda
30 Aug 2025 //
BIOSPACE
Teva’s Generics Liraglutide Receives Approval in US
27 Aug 2025 //
FDA
MedImpact offers low-cost ustekinumab-aekn biosimilar to US
18 Aug 2025 //
BUSINESSWIRE
Senores Acquires ANDAs from Teva Pharmaceuticals USA
14 Aug 2025 //
INDPHARMAPOST
FDA Approves Teva`s Ajovy for Migraine Prevention in Children
06 Aug 2025 //
REUTERS
Teva`s Biologics Ajovy Receives Suppl Approval in US
05 Aug 2025 //
FDA
Teva Execs Unfazed by New Pharmaceutical Tariffs
30 Jul 2025 //
FIERCE PHARMA
Teva`s Q2 2025 Growth Streak Continues; Ups 2025 Revenue Forecast
30 Jul 2025 //
GLOBENEWSWIRE
J&J Defeats Generic Drugmakers in Appeal Over Schizophrenia Drug
09 Jul 2025 //
REUTERS
Teva Earns Spot in TIME and Statista`s 2025 Most Sustainable
07 Jul 2025 //
ACCESSWIRE
Europe Must Restore Generic Manufacturing Autonomy: Teva Exec
01 Jul 2025 //
FIERCE PHARMA
Teva Releases Q2 2025 Aide Memoire
26 Jun 2025 //
GLOBENEWSWIRE
Teva Conference Call on Q2 2025 Results on July 30
25 Jun 2025 //
GLOBENEWSWIRE
Teva’s PEARL Study: AJOVY® Effective for Chronic Migraine
23 Jun 2025 //
GLOBENEWSWIRE
Teva and Fosun Pharma Partner to Develop Anti-PD1-IL2 Therapy
16 Jun 2025 //
GLOBENEWSWIRE
Teva Wins Power of Partnership Award for Global Health Impact
10 Jun 2025 //
ACCESSWIRE
Health Canada Issues Recalls of Teva`s Seasonale Tablet
06 Jun 2025 //
HEALTH CANADA
Health Canada Issues Recalls of Teva`s Seasonique tablet
06 Jun 2025 //
HEALTH CANADA
Teva 2024 Report: Health System Strengthening & Capacity Building
06 Jun 2025 //
ACCESSWIRE
Teva Announces Early Tender Results and Raises Tender Pool Cap
03 Jun 2025 //
GLOBENEWSWIRE
Teva Announces Pricing and Early Acceptance of Debt Tender Offer
03 Jun 2025 //
GLOBENEWSWIRE
Teva Shares Uzedy, TEV-‘749 Data In Schizophrenia At ASCO
30 May 2025 //
GLOBENEWSWIRE
Teva Data Shows Undertreated Tardive Dyskinesia at Psych Congress
30 May 2025 //
GLOBENEWSWIRE
Teva Reaffirms "pivot to Growth" Strategy with 2025 Launch
29 May 2025 //
GLOBENEWSWIRE
Teva, Biolojic Begin IND Studies for BD9 in Asthma, Dermatitis
27 May 2025 //
GLOBENEWSWIRE
Teva to Present at Healthcare Conferences in June
27 May 2025 //
GLOBENEWSWIRE
Teva`s Celiac Disease Candidate Gets FDA Fast Track Designation
27 May 2025 //
GLOBENEWSWIRE
Teva Increases Maximum Tender Amount and Pool Caps for Debt Offer
22 May 2025 //
GLOBENEWSWIRE
Fitch Upgrades Teva Rating to BB+ for Successful Growth Strategy
20 May 2025 //
GLOBENEWSWIRE
Teva Upsizes and Prices $2.3B Senior Notes to Repay Debt
20 May 2025 //
GLOBENEWSWIRE
Teva Launches $2B Senior Notes Offering
19 May 2025 //
GLOBENEWSWIRE
Teva Announces $2B Debt Tender Offers For Notes Due 2026-2031
19 May 2025 //
GLOBENEWSWIRE
Moody`s Investor Upgrades Teva Amid Success of Growth Strategy
15 May 2025 //
GLOBENEWSWIRE
Teva`s 2024 Healthy Future Report Highlights Sustainability Program
13 May 2025 //
ACCESSWIRE
Teva 2024 Report Shows Progress on Sustainability Goals
12 May 2025 //
GLOBENEWSWIRE
Teva to Host Innovation & Strategy Day on May 29 in New York City
07 May 2025 //
GLOBENEWSWIRE
